pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,396 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1789Endpoints1393Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12362Rare Disease3231Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • Experts highlight lack of reliable biomarkers for melanoma immunotherapy response
    Dr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, discussed the ongoing difficulty of predicting which patients with metastatic melanoma will benefit from immune…
    onclive · 6mo agoNegative↗ source
  • Utah invests in AI supercomputer to boost health research and biotech innovation
    State of Utah announced a major investment in artificial intelligence and high-performance computing infrastructure aimed at accelerating health research. The new AI supercomputer, managed by the…
    onclive · 6mo agoPositive↗ source
← prev
page 166 of 176
next →
111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1064
Pain778
Endocrinology & Metabolism777
Nephrology762
Expert Consensus Offers Guidance on Evolving Multiple Myeloma Treatment Strategies
A 2025 expert consensus presented at the Bridging the Gaps meeting highlighted how quickly multiple myeloma care is changing and gave clinicians practical advice for navigating expanding treatment…
onclive · 6mo agoNeutral↗ source
  • Experts outline PET-CT, biopsy and mutation testing to guide therapy in relapsed CLL
    In a recent discussion, clinicians described the workup for patients with progressive chronic lymphocytic leukemia (CLL). They emphasized using PET‑CT imaging and excisional lymph node biopsy when…
    onclive · 6mo agoNeutral↗ source
  • Experts discuss mutation testing and patient factors to guide second-line CLL therapy after BTK inhibitor resistance
    A 66-year-old man who was diagnosed with chronic lymphocytic leukemia five years ago and initially had an unmutated IGHV profile without TP53 alteration has been on continuous covalent BTK inhibito…
    onclive · 6mo agoNeutral↗ source
  • Daraxonrasib uniquely targets active KRAS in pancreatic cancer, says MD Anderson expert
    Dr Shubham Pant, a professor in the Department of Gastrointestinal Medical Oncology at MD Anderson Cancer Center, explained the mechanism of daraxonrasib in a recent commentary. The oral, potent R…
    onclive · 6mo agoPositive↗ source
  • CellCentric secures $220 million Series D to advance multiple myeloma oral therapy
    CellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round. The capital will be used to complete development and prepare for…
    Endpoints · 6mo agoDealPositive↗ source
  • Bayer agrees to acquire ophthalmology biotech Perfuse Therapeutics for $300 million upfront
    Bayer announced it will purchase Perfuse Therapeutics, a company focused on eye-disease treatments, for an upfront payment of $300 million. The acquisition includes Perfuse's mid-stage program that…
    Endpoints · 6mo agoDealNeutral↗ source
  • Amgen and AbbVie report Inflation Reduction Act negotiations dent Q1 sales
    Amgen and AbbVie disclosed in their first-quarter earnings that the Inflation Reduction Act is already affecting their sales. The companies said the first set of drug-price negotiations required b…
    Endpoints · 6mo agoEarningsNegative↗ source
  • Sanofi requests removal of teplizumab from FDA fast-track voucher program after director dispute
    Sanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Color Health expands into cancer treatment coordination with virtual tumor boards
    Color Health, a telehealth firm that currently coordinates cancer screening, is moving into providing and coordinating actual cancer care services. CEO Othman Laraki says the growing complexity of…
    STAT · 6mo agoPositive↗ source
  • FDA authorizes fruit-flavored vapes amid political pressure, sparking debate over youth risk and quitting aid
    The U.S. Food and Drug Administration granted its first authorization for fruit-flavored e-cigarettes on Tuesday, adding mango- and blueberry-tasting products from Los Angeles-based Glas to its app…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Madrigal's Rezdiffra sales top forecasts as Gilead announces job cuts
    Madrigal Pharmaceuticals reported first‑quarter sales of its MASH drug Rezdiffra at $311 million, roughly $10 million above analyst expectations, according to TD Cowen. The outperformance highligh…
    Endpoints · 6mo agoEarningsNeutral↗ source
  • Former Orbital scientists launch ParcelBio with $13 million seed round to boost mRNA therapy durability
    Two former Orbital Therapeutics scientists, Chris Carlson and David Weinberg, have founded a new company called ParcelBio. The startup aims to address a technical limitation that has hindered the…
    Endpoints · 6mo agoDealPositive↗ source
  • Experts preview top HR+ and HER2+ breast cancer abstracts ahead of ASCO 2026
    Preparations are under way for the 2026 ASCO Annual Meeting, and breast cancer updates are generating strong interest among clinicians. Leading oncologists including Dr. Yara Abdou of UNC, Dr. VK…
    onclive · 6mo agoNeutral↗ source
  • PhRMA launches seven-figure ad campaign against 340B drug discount program
    PhRMA, the leading pharmaceutical lobbying group, announced a new advertising push aimed at the federal 340B drug discount program. The campaign, described as a seven-figure effort, is set to begi…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Phase 3 MANEUVER trial shows pimicotinib improves response and pain in advanced TGCT, supporting FDA NDA acceptance
    The phase 3 MANEUVER study evaluated pimicotinib in patients with advanced diffuse tenosynovial giant cell tumor. The trial compared the oral agent to placebo and collected both clinical and patien…
    onclive · 6mo agoPositive readoutPositive↗ source
  • BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidate
    BeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
    Endpoints · 6mo agoNegative↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Health AI progress limited by bad data, newsletter notes
    The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine. The author explains that many existing datasets contain…
    STAT · 6mo agoNeutral↗ source
  • Higher PD-L1 levels linked to poorer outcomes in EGFR-mutated NSCLC treated with first-line osimertinib
    Dr. Jonathan Wennan Lee, a chief hematology/oncology fellow at Weill Cornell Medicine, discussed the emerging role of PD-L1 as a predictive biomarker for first-line osimertinib resistance in EGFR-m…
    onclive · 6mo agoNegative readoutNeutral↗ source
  • Experts discuss next-generation pathology and precision care for non-small cell lung cancer in new CME podcast
    The CME podcast released on May 6, 2026 brings together Sanja Dacic, Isabel Preeshagul, and Soo-Ryum (Stewart) Yang to review recent advances in pathology for non-small cell lung cancer. The exper…
    onclive · 6mo agoNeutral↗ source
  • HHS focuses on overmedication as cruise ship hantavirus outbreak prompts port change
    The Health and Human Services department announced new efforts to curb excessive prescribing, highlighting concerns about overmedication in the United States. At the same time, a cruise ship ancho…
    STAT · 6mo agoNeutral↗ source
  • OpenAI’s health AI policy blueprint seen as reasonable yet self‑serving, experts say
    OpenAI has expanded its health‑focused AI tools, rolling out ChatGPT Health for consumers, a hospital‑oriented ChatGPT for Healthcare, and a version for clinicians. Alongside the clinician chatbot,…
    STAT · 6mo agoRegulatoryNegative↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 6mo agoRegulatoryNeutral↗ source